Read by QxMD icon Read

Journal of Cardiovascular Pharmacology

Stefano Toldo, Adolfo Gabriele Mauro, Zachary Cutter, Benjamin W Van Tassell, Eleonora Mezzaroma, Marco Giuseppe Del Buono, Andrea Prestamburgo, Nicola Potere, Antonio Abbate
BACKGROUND: Activation of the NLRP3 inflammasome is a primary driver of sterile inflammation in response to myocardial ischemia reperfusion. Pharmacologic inhibitors of the NLRP3 inflammasome are being developed. We proposed that OLT1177 (dapansutrile), a novel NLRP3 inflammasome inhibitor, could preserve myocardial function after ischemia reperfusion injury in the mouse. METHODS: We used an experimental murine model of myocardial ischemia reperfusion injury through transient ligation of the left coronary artery, and measured the effects of OLT1177 (6, 60 or 600 mg/kg intraperitoneal dose) on infarct size at pathology and on systolic cardiac function at echocardiography...
February 8, 2019: Journal of Cardiovascular Pharmacology
Tobias Schupp, Michael Behnes, Christel Weiß, Christoph Nienaber, Siegfried Lang, Linda Reiser, Armin Bollow, Gabriel Taton, Thomas Reichelt, Dominik Ellguth, Niko Engelke, Thomas Bertsch, Muharrem Akin, Kambis Mashayekhi, Martin Borggrefe, Ibrahim Akin
This study sought to assess the prognostic impact of treatment with angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) on recurrences of ventricular tachyarrhythmias in recipients of implantable cardioverter defibrillators (ICD).Using a large retrospective registry including consecutive ICD recipients with documented episodes of ventricular tachycardia (VT) or fibrillation (VF) from 2002 to 2016, those patients treated with ACEi/ARB were compared to patients without (non-ACEi/ARB)...
February 8, 2019: Journal of Cardiovascular Pharmacology
Wenke Cheng, Xi Jia, Jianting Li, Wensi Cheng, Zhou Liu, Zongbin Lin, Chong Yang
Statins have been suggested in previous studies to play a protective role in experimental cerebral aneurysm (CA) models; however, no evidence supports that the application of statins can protect against aneurysm rupture in humans, and the risks of lipid levels and aneurysms remain unknown. Therefore, this meta-analysis aimed to summarize and update the epidemiological evidence to systematically assess the relationships of statins therapy and hyperlipidemia with the incidence, rupture, post-repair mortality and all-cause mortality of abdominal aortic aneurysm (AAA) and CA...
January 25, 2019: Journal of Cardiovascular Pharmacology
Fang Yi, Wenbo Hou, Chao Zhou, Yuxia Yin, Shoutao Lu, Cuihai Duan, MingKun Cao, Maoquan Li, Egon Steen Toft, Haijun Zhang
BACKGROUND: Radiofrequency ablation (RFA) and antiarrhythmic drugs (AAD) are the main treatments used for atrial fibrillation (AF). In recent years, a number of articles comparing the two treatments have begun to emerge. Though, the influence of follow-up time in the meta-analysis was not considered in these articles. However, more recently, large-scale clinical trial articles have included follow-up with the patients up to five years after treatment. Therefore, the aim of this study was to assess the impact of variable follow-up times on the recurrence of AF by observing both the short-term and long-term efficacy and safety of catheter ablation and antiarrhythmic drugs for the treatment of AF...
January 25, 2019: Journal of Cardiovascular Pharmacology
Feifei Wang, Jun Guo, Aidong Zhang
AIMS: To evaluate the efficacy and safety of using genetic information to guide warfarin dosing in the Chinese population. METHODS: This meta-analysis was conducted among the published, randomized, controlled trials (RCTs) in the Chinese population comparing genotyped-guided warfarin dosing (PG group) with clinical or standard warfarin dosing (STD group). RCTs published on or before January 2018 were identified using the PubMed, Embase, Cochrane Library, CNKI, Chinese VIP database and Chinese Wanfang databases...
January 25, 2019: Journal of Cardiovascular Pharmacology
Isil Ozakca
The antihypertrophic effect of nebivolol over cardioselective beta-blockers (β-blockers) is attributed to the activation of cardiac nitric oxide signaling. However, the precise role of nebivolol on hypertrophied cardiomyocytes remains unclear. In the current study, in vitro cardiomyocyte hypertrophy model was induced with isoprenaline (10μM), angiotensin II (1μM) and phenylephrine (20μM) in neonatal cardiomyocytes isolated from 0-2 days old Sprague-Dawley rats. In addition to hypertrophic agents, cardiomyocytes were treated with nebivolol (1μM), metoprolol (10μM), N(ω)-nitro-L-arginine methyl ester(L-NAME) (100μM), KT5823 (1μM), DETA-NONOate (1-10μM) and BAY412272 (10μM)...
December 27, 2018: Journal of Cardiovascular Pharmacology
Ge Gao, Shiliang Jiang, Lili Ge, Shanshan Zhang, Chungang Zhai, Wenqiang Chen, Shujian Sui
Atorvastatin is a lipid-regulating drug that is commonly used in clinical practice and can stabilize plaques. Increasing evidence shows that statins have anti-heart failure effects, but their specific mechanism is not clear. The purpose of this study was to investigate the cardioprotective effects of atorvastatin on heart failure in rats and its mechanism. Continuous intraperitoneal injection of 2.5 mg/kg/w doxorubicin for 6 weeks, with a cumulative dose of 15 mg/kg, was used to induce a rat model of heart failure...
December 10, 2018: Journal of Cardiovascular Pharmacology
Lourdes Vicent, Alberto Esteban-Fernández, Manuel Gómez-Bueno, Javier De-Juan, Pablo Díez-Villanueva, Ángel Manuel Iniesta, Ana Ayesta, Hugo González-Saldívar, Antonio Rojas-González, Ramón Bover-Freire, Diego Iglesias, Marcos García-Aguado, Jesús A Perea-Egido, Manuel Martínez-Sellés
Sacubitril/valsartan (SV) is a new therapy in heart failure with reduced ejection fraction. Our aim was to determine the efficacy and safety of this drug daily clinical practice.We performed a multicenter registry in 10 hospitals. All patients who started SV from October 2016 to March 2017 on an outpatient basis were included.A total of 427 patients started treatment with SV. Mean follow-up was 7.0±0.1 months. Forty-nine patients (11.5%) discontinued SV, and 12 (2.8%) died. SV discontinuation was associated with higher cardiovascular (hazard ratio [HR] 13...
December 10, 2018: Journal of Cardiovascular Pharmacology
Stefan Momčilović, Jasmina R Milovanović, Slobodan M Janković, Andriana Jovanović, Suzana Tasić-Otašević, Dragana Stanojević, Miroslav Krstić, Sonja Šalinger-Martinović, Danijela Djordjević Radojković, Miodrag Damjanović, Milan Živković, Bojan Maričić, Goran Ranković, Aleksandar Mihajlović, Valentina N Nikolić
To date, many questions about the extent and cause of pharmacokinetic variability of even the most widely studied and prescribed β1-adrenergic receptor blockers, such as metoprolol and bisoprolol, remain unanswered. Given that there are still no published population pharmacokinetic (PopPK) analyses of bisoprolol in routinely treated patients with acute coronary syndrome (ACS), the aim of this study was to determine its PK variability in 71 Serbian patients with ACS. PopPK analysis was carried out using a non-linear mixed effects model (NONMEM), version 7...
December 10, 2018: Journal of Cardiovascular Pharmacology
Manisha Nautiyal, Hossam A Shaltout, Mark C Chappell, Debra I Diz
Hypertensive transgenic (mRen2)27 rats exhibit impaired baroreflex sensitivity (BRS) for control of heart rate (HR). Intracerebroventricular (ICV) infusion of Ang-(1-7) improves indices of vagal BRS independent of lowering mean arterial pressure (MAP), while AT1 receptor blockade normalizes MAP and indices of sympathetic tone without correcting the vagal BRS. Scavenging cellular reactive oxygen species (ROS) with tempol in brain fails to correct either hypertension or sympathovagal balance in these animals, despite reports that mitochondrial ROS contributes to Ang II-infusion hypertension...
December 10, 2018: Journal of Cardiovascular Pharmacology
Amy X Du, Cynthia M Westerhout, Finlay A McAlister, Miriam Shanks, Gavin Y Oudit, D Ian Paterson, Mikael Hanninen, Jissy Thomas, Justin A Ezekowitz
Little is known about the dosing and tolerability of sacubitril/valsartan (LCZ696; Entresto™, Quebec, Canada) in a non-clinical trial population. This study was conducted to evaluate the use and tolerability of sacubitril/valsartan in patients followed at a multidisciplinary heart failure clinic. We performed a retrospective chart review of 126 patients with heart failure, initiated on sacubitril/valsartan, and seen at a specialty heart failure clinic between August 1, 2015 and August 1, 2017. We defined the target dose of sacubitril/valsartan as 200 mg B...
December 10, 2018: Journal of Cardiovascular Pharmacology
Jing Ma, Dan Zhao, Xiaolin Wang, Chuanrui Ma, Ke Feng, Shuang Zhang, Yuanli Chen, Yan Zhu, Xiumei Gao, Buchang Zhao, Yong Wang, Ke Qian, Xiaoju Li, Yajun Duan, Jihong Han, Xiaoxiao Yang
Disorders of lipid metabolism and inflammation play an important role in atherosclerosis. LongShengZhi capsule (LSZ), a Chinese herbal medicine, has been used for treatment of patients with vascular diseases for many years. Herein, we determined the effect of LSZ on the progression of established atherosclerotic lesions in apoE deficient (apoE) mice. ApoE mice were pre-fed high-fat diet (HFD) for 8 weeks to induce atherosclerosis, then started with LSZ treatment contained in HFD for 10 weeks. Although LSZ had little effect on HFD-induced hypercholesterolemia, it substantially reduced en face and sinus aortic lesions...
December 10, 2018: Journal of Cardiovascular Pharmacology
Lirong Li, Shaohua Ren, Xudong Hao, Zigang Zhen, Hongming Ji
Our aim was to explore the efficacy of minimally invasive intervention in patients with acute cerebral infarction (ACI). Seventy patients with ACI were randomized into either an experimental group or a control group. In addition to the regular treatment, patients in the control group also received intravenous thrombolysis with urokinase, while patients in the other group underwent percutaneous transluminal cerebral angioplasty and stenting. Metrics included recanalization rate, serum cytokines, fibrinolytic markers and 36-Item Short Form Health Survey score were compared between the two groups...
December 4, 2018: Journal of Cardiovascular Pharmacology
Martin Šíma, Ondřej Slanař
Feyz L et al. Therapeutic drug monitoring to assess drug adherence in assumed resistant hypertension: A comparison with directly observed therapy in 3 nonadherent patients. J Cardiovascular Pharmacol. 2018 Aug;72(2):117-120.
November 30, 2018: Journal of Cardiovascular Pharmacology
Toru Kawada, Toji Yamazaki, Tsuyoshi Akiyama, Yohsuke Hayama, Masaru Sugimachi
Although hypothermia suppresses myocardial ischemia/reperfusion injury, whether it also protects the myocardium against cellular stresses such as chemical anoxia and calcium overload remains unknown. We examined the effect of mild hypothermia (33 °C) on myocardial injury during ischemia/reperfusion, local administration of sodium cyanide (chemical anoxia), or local administration of maitotoxin (forced Ca overload) using cardiac microdialysis applied to the feline left ventricle. Baseline myoglobin levels (in ng/ml) were 237 ± 57 and 150 ± 46 under normothermia and hypothermia, respectively (mean ± SE, n = 6 probes each)...
November 30, 2018: Journal of Cardiovascular Pharmacology
Xin-Wen Liu, Meng-Kai Lu, Hui-Ting Zhong, Li-Hong Wang, Yong-Ping Fu
BACKGROUND AND OBJECTIVE: Panax Notoginseng Saponins (PNS) is a formula of Chinese Medicine commonly used for treating ischemia myocardial in China. However, its mechanism of action is yet unclear. This study investigated the effect and the mechanism of PNS on myocardial ischemia-reperfusion injury via the hypoxia-inducible factor 1α(HIF-1α)/bcl-2/adenovirus E1B19kDa-interacting protein3(BNIP3) pathway of autophagy. METHODS: We constructed a rat model of myocardial injury, and compared among4 groups (n=10, each): Sham(the sham-operated group), IR(the ischemia-reperfusion group), the PNS-low and -high dose groups were pretreated with PNS (30 and 60 mg/kg, respectively)...
November 30, 2018: Journal of Cardiovascular Pharmacology
Frans Hh Leenen, Monir Ahmad, Yannick Marc, Catherine Llorens-Cortes
AIMS: Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure (HF) in rats post myocardial infarction (MI). The present study evaluated effectiveness of systemic treatment with firibastat compared to AT1R blocker, losartan. METHODS AND RESULTS: MI was induced by ligation of left coronary artery in male Wistar rats. Rats were treated from 1 to 5 weeks post MI in protocol 1 with vehicle, or firibastat at 50 mg/kg/day sc or 150 mg/kg/day oral, once daily and in protocol 2, with vehicle, firibastat 150 mg/kg or losartan 50 mg/kg oral twice daily...
November 30, 2018: Journal of Cardiovascular Pharmacology
Joseph A Hill, Stefan Agewall, Adrian Baranchuk, George W Booz, Jeffrey S Borer, Paolo G Camici, Peng-Sheng Chen, Anna F Dominiczak, Çetin Erol, Cindy L Grines, Robert Gropler, Tomasz J Guzik, Markus K Heinemann, Ami E Iskandrian, Bradley P Knight, Barry London, Thomas F Lüscher, Marco Metra, Kiran Musunuru, Brahmajee K Nallamothu, Andrea Natale, Sanjeev Saksena, Michael H Picard, Sunil V Rao, Willem J Remme, Robert S Rosenson, Nancy K Sweitzer, Adam Timmis, Christiaan Vrints
No abstract text is available yet for this article.
February 2019: Journal of Cardiovascular Pharmacology
Mina Nishi, Kiyoaki Yonesu, Hideki Tagawa, Mikio Kato, Shinji Marumoto, Takahiro Nagayama
This study was designed to characterize the pharmacological profile of DS37001789, which is a structurally novel piperazine derivative that acts as urotensin II (U-II) receptor antagonist. DS37001789 inhibited [I]-U-II binding to human GPR14, U-II receptor, with an IC50 value 0.9 nM. Its potency was superior to that of ACT-058362, a nonpeptide U-II receptor antagonist whose IC50 was 120 nM. Human U-II-induced vascular contraction was blocked by DS37001789. The dose-response curve of DS37001789 in rats and monkeys did not show species differences, and it shifted to the right without any effects on the maximum vascular response...
January 2019: Journal of Cardiovascular Pharmacology
Antoine Herpain, Stefaan Bouchez, Massimo Girardis, Fabio Guarracino, Johann Knotzer, Bruno Levy, Tobias Liebregts, Piero Pollesello, Sven-Erik Ricksten, Hynek Riha, Alain Rudiger, Fabio Sangalli
Levosimendan is an inodilator that promotes cardiac contractility primarily through calcium sensitization of cardiac troponin C and vasodilatation via opening of adenosine triphosphate-sensitive potassium (KATP) channels in vascular smooth muscle cells; the drug also exerts organ-protective effects through a similar effect on mitochondrial KATP channels. This pharmacological profile identifies levosimendan as a drug that may have applications in a wide range of critical illness situations encountered in intensive care unit medicine: hemodynamic support in cardiogenic or septic shock; weaning from mechanical ventilation or from extracorporeal membrane oxygenation; and in the context of cardiorenal syndrome...
January 2019: Journal of Cardiovascular Pharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"